Drug Profile
Pentosan polysulfate sodium - bene-Arzneimittel/ReqMed
Alternative Names: AK-150; Elmiron; NaPPSLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator bene-Arzneimittel; ReqMed
- Developer Asahi Kasei; Bayer; bene-Arzneimittel; Multiplex Pharma Holdings; Ortho-McNeil Pharmaceutical; Teva Pharmaceutical Industries
- Class Analgesics; Anti-inflammatories; Antiallergics; Anticoagulants; Antihyperlipidaemics; Antiretrovirals; Antithrombotics; Antivirals; Glycosaminoglycans; Polymers; Polysaccharides; Small molecules; Sulfuric acids
- Mechanism of Action Cell membrane permeability inhibitors; Non-nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Marketed Interstitial cystitis; Pain
- Phase II Mucopolysaccharidosis I
- Phase I/II Mucopolysaccharidosis VI
- Discontinued Osteoarthritis; Spinal cord disorders
Most Recent Events
- 13 Nov 2019 The National Institute for Health and Care Excellence (NICE) recommends use of pentosan polysulfate sodium for Interstitial cystitis in United Kingdom
- 11 Nov 2019 Consilient Health announces intention to launch pentosan polysulfate sodium for Interstitial cystitis in Scotland
- 11 Nov 2019 The Scottish Medicines Consortium recommends use of pentosan polysulfate sodium for Interstitial cystitis in Scotland